SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-22-021905
Filing Date
2022-04-27
Accepted
2022-04-27 16:05:51
Documents
5
Period of Report
2022-06-08

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT def14a0422_protarathera.htm DEF 14A 1137230
2 GRAPHIC tprotara_logo.jpg GRAPHIC 99265
3 GRAPHIC tproxy_001.jpg GRAPHIC 1402210
4 GRAPHIC tproxy_002.jpg GRAPHIC 1067687
5 GRAPHIC tsign_mary.jpg GRAPHIC 16039
  Complete submission text file 0001213900-22-021905.txt   4699784
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36694 | Film No.: 22859514
SIC: 2836 Biological Products, (No Diagnostic Substances)